The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...
Ron Ofri, DVM, PhD, DECVO, provided veterinary professionals at the Veterinary Meeting & Expo conference ways to make ophthalmic exams less intimidating for general practitioners ...
Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Abnormalities of the vitreoretinal interface may contribute to important retinal pathologies such as diabetic retinopathy, diabetic macular edema and age-related macular degeneration. The ...
Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback